Latest & greatest articles for lorazepam

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lorazepam or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lorazepam and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lorazepam

1. Lorazepam

Lorazepam Top results for lorazepam - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for lorazepam The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

2. Efficacy of Gabapentin versus Lorazepam in alcohol withdrawal syndrome: a systematic review and meta-analysis

Efficacy of Gabapentin versus Lorazepam in alcohol withdrawal syndrome: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

3. Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial. The use of benzodiazepines to control agitation in delirium in the last days of life is controversial.To compare the effect of lorazepam vs placebo as an adjuvant to haloperidol for persistent agitation in patients with delirium in the setting of advanced cancer.Single-center, double-blind, parallel-group, randomized clinical (...) trial conducted at an acute palliative care unit at MD Anderson Cancer Center, Texas, enrolling 93 patients with advanced cancer and agitated delirium despite scheduled haloperidol from February 11, 2014, to June 30, 2016, with data collection completed in October 2016.Lorazepam (3 mg) intravenously (n = 47) or placebo (n = 43) in addition to haloperidol (2 mg) intravenously upon the onset of an agitation episode.The primary outcome was change in Richmond Agitation-Sedation Scale (RASS) score (range

2017 JAMA Controlled trial quality: predicted high

4. A comparison of lorazepam and diazepam as initial therapy in convulsive status epilepticus

A comparison of lorazepam and diazepam as initial therapy in convulsive status epilepticus A comparison of lorazepam and diazepam as initial therapy in convulsive status epilepticus A comparison of lorazepam and diazepam as initial therapy in convulsive status epilepticus Cock H R, Schapira A H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Lorazepam was compared with diazepam as first-line treatment for convulsive status epilepticus (CSE). The dose of lorazepam was 4 mg intravenously (i.v.), repeated up to 2 times. The dose of diazepam was 10 mg i.v., repeated up to 3 times. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients aged over

2002 NHS Economic Evaluation Database.

5. The Lorazepam and Diazepam Protocol for Catatonia Due to General Medical Condition and Substance in Liaison Psychiatry. Full Text available with Trip Pro

The Lorazepam and Diazepam Protocol for Catatonia Due to General Medical Condition and Substance in Liaison Psychiatry. The lorazepam-diazepam protocol had been proved to rapidly and effectively relieve catatonia in patients with schizophrenia or mood disorder. This study aims to investigate the efficacy of lorazepam-diazepam protocol in catatonia due to general medical conditions (GMC) and substance.Patients with catatonia that required psychiatric intervention in various settings of a medical (...) center were included. The lorazepam-diazepam protocol had been used to treat the catatonia due to GMC or substance according to DSM-IV criteria. The treatment response had been assessed by two psychiatrists.Eighteen (85.7%) of 21 catatonic patients due to GMC or substance became free of catatonia after the lorazepam-diazepam protocol. Five (23.8%) of the 21 patients had passed away with various causes of death and wide range of time periods after catatonia.Our results showed that the lorazepam

2017 PLoS ONE

6. Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save (...) this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your

2018 Clinical Trials

7. Intramuscular haloperidol-promethazine sedates violent or agitated patients more quickly than intramuscular lorazepam Full Text available with Trip Pro

Intramuscular haloperidol-promethazine sedates violent or agitated patients more quickly than intramuscular lorazepam Intramuscular haloperidol-promethazine sedates violent or agitated patients more quickly than intramuscular lorazepam | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Intramuscular haloperidol-promethazine sedates violent or agitated patients more quickly than intramuscular lorazepam Article Text Therapeutics

2006 Evidence-Based Mental Health

8. Comparing the efficacy of sodium valproate and levetiracetam following initial lorazepam in elderly patients with generalized convulsive status epilepticus (GCSE): A prospective randomized controlled pilot study. Full Text available with Trip Pro

Comparing the efficacy of sodium valproate and levetiracetam following initial lorazepam in elderly patients with generalized convulsive status epilepticus (GCSE): A prospective randomized controlled pilot study. This randomized control study was conducted to compare the efficacy of sodium valproate (SVP) and levetiracetam (LEV) following initial intravenous lorazepam in elderly patients (age: >60years) with generalized convulsive status epilepticus (GCSE) and to identify predictors of poor (...) seizure control.A total of 118 patients (mean age: 67.5 ± 7.5 years, M:F = 1.6:1), who had presented with GCSE were randomized into the SVP or LEV treatment arms. All patients received initial intravenous lorazepam (0.1 mg/kg) followed by one of the two antiepileptic drugs (AEDs), parenteral SVP (20-25 mg/kg) or LEV (20-25 mg/kg). Those who failed to achieve control with the initial AED, were crossed over to receive the other AED. One-hundred patients (SVP = 50; LEV = 50) completed the study.SE could

2019 Seizure Controlled trial quality: uncertain

9. The effectiveness of ibuprofen and lorazepam combination therapy in treating the symptoms of acute Migraine: A randomized clinical trial Full Text available with Trip Pro

The effectiveness of ibuprofen and lorazepam combination therapy in treating the symptoms of acute Migraine: A randomized clinical trial Migraine is a common, episodic and debilitating disease. The migraineur not only suffers from pain, but also lives with a diminished to poor quality of life. Several medicinal therapies are used to abate the debilitating symptoms of this disease.The present study was conducted to determine the effectiveness of Ibuprofen and Lorazepam combination therapy (...) randomly divided into three groups of 30. The first group was administered 200 mg Ibuprofen capsules, the second group 400 mg Ibuprofen capsules and the third group a combination of 200 mg Ibuprofen capsules and 1 mg Lorazepam tablets. The medications were taken in the presence of the researcher. A checklist was used to assess the severity of headache and other migraine symptoms such as nausea, vomiting, photophobia and phonophobia in the patients, before and two hours after the intervention. Data were

2017 Electronic physician Controlled trial quality: uncertain

10. Single dose phenobarbital in addition to symptom-triggered lorazepam in alcohol withdrawal. (Abstract)

Single dose phenobarbital in addition to symptom-triggered lorazepam in alcohol withdrawal. The purpose of this study was to evaluate the safety and efficacy of a single parenteral dose of phenobarbital in addition to symptom-triggered lorazepam for the acute management of alcohol withdrawal syndrome (AWS).This was a retrospective chart review of adult patients who presented to the Emergency Department with moderate or severe symptoms of alcohol withdrawal. Patients were included (...) if they received at least 4 mg of lorazepam through the hospital's Alcohol Withdrawal Order Set on hospital day one. Patients who received a single parenteral dose of phenobarbital on hospital day one were compared to those who did not.Forty patients received phenobarbital and 38 patients received lorazepam only. Median daily lorazepam requirements, disposition, hospital length of stay, and median maximum daily CIWA-Ar scores were not statistically significant different between the groups. Significantly more

2019 American Journal of Emergency Medicine

11. Lorazepam vs diazepam for pediatric status epilepticus: a randomized clinical trial. Full Text available with Trip Pro

Lorazepam vs diazepam for pediatric status epilepticus: a randomized clinical trial. Benzodiazepines are considered first-line therapy for pediatric status epilepticus. Some studies suggest that lorazepam may be more effective or safer than diazepam, but lorazepam is not Food and Drug Administration approved for this indication.To test the hypothesis that lorazepam has better efficacy and safety than diazepam for treating pediatric status epilepticus.This double-blind, randomized clinical trial (...) was conducted from March 1, 2008, to March 14, 2012. Patients aged 3 months to younger than 18 years with convulsive status epilepticus presenting to 1 of 11 US academic pediatric emergency departments were eligible. There were 273 patients; 140 randomized to diazepam and 133 to lorazepam.Patients received either 0.2 mg/kg of diazepam or 0.1 mg/kg of lorazepam intravenously, with half this dose repeated at 5 minutes if necessary. If status epilepticus continued at 12 minutes, fosphenytoin

2014 JAMA Controlled trial quality: predicted high

12. A Comparative Study of the Clinical Efficacy and Safety of Lorazepam and Chlordiazepoxide in Alcohol Dependence Syndrome Full Text available with Trip Pro

A Comparative Study of the Clinical Efficacy and Safety of Lorazepam and Chlordiazepoxide in Alcohol Dependence Syndrome Currently, benzodiazepines are the preferred drugs in the management of alcohol withdrawal symptoms. Chlordiazepoxide and diazepam, the most frequently used drugs have a long duration of action and are converted to active metabolites in the liver, while lorazepam is shorter acting, with no active metabolites.To compare and evaluate the safety and efficacy of lorazepam (...) and chlordiazepoxide in patients with alcohol dependence syndrome with symptoms of alcohol withdrawal.This was a prospective, randomized, double-blind, study carried out at a teaching hospital in Bangalore. Sixty patients aged ≥18 y with alcohol dependence syndrome with mild-to-moderate withdrawal symptoms were allocated at a ratio of 1:1 to either lorazepam or chlordiazepoxide, by means of a computer-generated randomization chart. Thirty patients each were started with lorazepam tablets 8 mg/day

2015 Journal of clinical and diagnostic research : JCDR Controlled trial quality: uncertain

13. The Relationship of UGT2B15 Pharmacogenetics and Lorazepam for Anxiety Full Text available with Trip Pro

The Relationship of UGT2B15 Pharmacogenetics and Lorazepam for Anxiety Anxiety affects over 260 million people worldwide. Benzodiazepines are a class of agents used in combination with other therapies for the management of anxiety. Lorazepam is a commonly prescribed benzodiazepine metabolized by uridine 5'-diphosphate-glucuronosyltransferases. Herein, we discuss recent findings regarding the pharmacogenetics of uridine 5'-diphosphate-glucuronosyltransferase 2B15 (UGT2B15), lorazepam, and its

2018 Cureus

14. Comparative amnesic and sedative effects of lorazepam and oxazepam in healthy volunteers. (Abstract)

Comparative amnesic and sedative effects of lorazepam and oxazepam in healthy volunteers. Oxazepam and its chlorinated derivative, lorazepam, have similar half-lives but differing potencies. This study compared the effects of these two benzodiazepines with a placebo on memory, mood and psychomotor function. Thirty six volunteers took part in a double-blind, independent groups design. Subjects completed a battery of tests before and 2.5 h after drug administration. Lorazepam 2 mg produced more (...) profound subjective and motor sedation than oxazepam 30 mg, and this in turn produced a similar, global pattern of impairments across a wide range of tasks. However, lorazepam produced greater decrements than oxazepam on a task involving episodic memory even when sedative effects were partialled out. We suggest that this finding may reflect either differential task sensitivities or a contribution of priming to performance on the explicit memory task.

2012 Journal of psychopharmacology (Oxford, England) Controlled trial quality: uncertain

15. Effect of adjuvant sleep hygiene psychoeducation and lorazepam on depression and sleep quality in patients with major depressive disorders: results from a randomized three-arm intervention. Full Text available with Trip Pro

Effect of adjuvant sleep hygiene psychoeducation and lorazepam on depression and sleep quality in patients with major depressive disorders: results from a randomized three-arm intervention. Sleep disturbances are a common co-occurring disturbance in patients with major depressive disorders (MDDs) and accordingly deserve particular attention. Using a randomized design, we investigated the effects of three different adjuvant interventions on sleep and depression among patients with MDD: a sleep (...) hygiene program (SHP), lorazepam (LOR), and their combination (SHP-LOR).A total of 120 outpatients with diagnosed MDD (mean age: 48.25 years; 56.7% females) and treated with a standard SSRI (citalopram at 20-40 mg at therapeutic level) were randomly assigned to one of the following three conditions: SHP (n=40), LOR (1 mg/d; n=40), SHP-LOR (1 mg/d; n=40). At the beginning and at the end of the study 8 weeks later, patients completed two questionnaires, the Pittsburgh Sleep Quality Index to assess sleep

2016 Neuropsychiatric disease and treatment Controlled trial quality: uncertain

16. Adverse performance effects of acute lorazepam administration in elderly long-term users: Pharmacokinetic and clinical predictors. Full Text available with Trip Pro

Adverse performance effects of acute lorazepam administration in elderly long-term users: Pharmacokinetic and clinical predictors. The benzodiazepine lorazepam is widely utilized in the treatment of elderly individuals with anxiety disorders and related conditions. Negative effects of acute lorazepam administration on cognitive performance, especially memory, have been reported in both previously untreated elderly and in individuals who have received short term (up to three weeks) treatment (...) with therapeutic doses. However, it remains unclear if these adverse cognitive effects also persist after long-term use, which is frequently found in clinical practice.Cognitively intact elderly individuals (n=37) on long-term (at least three months) daily treatment with lorazepam were studied using a double-blind placebo-controlled cross-over study design. Subjects were administered their highest daily unit dose of lorazepam (0.25-3.00 mg) or placebo on different days, approximately 1 week apart in a random

2014 Progress in neuro-psychopharmacology & biological psychiatry

17. Intravenous diazepam, midazolam and lorazepam in acute seizure control. (Abstract)

Intravenous diazepam, midazolam and lorazepam in acute seizure control. To evaluate the safety and efficacy of three benzodiazepine drugs: Lorazepam, Midazolam and Diazepam, when given parenterally in the control of acute seizure.One hundred and twenty children of either sex in the age group 6 month to 14 years brought convulsing to the pediatric emergency services, were enrolled in the study. These were randomised to three equal groups of 40 patients each; Group A-received diazepam, Group B (...) -received midazolam, Group C-received lorazepam. End of seizure episode (clinically) was defined as cessation of visible epileptic phenomenon or return of purposeful response to external stimuli within 15 min of drug administration. A stopwatch was used to measure various time intervals accurately. The patient's vitals were monitored and recorded in a predesigned performa. The primary outcome was the time to seizure cessation and secondary outcome was the side effects of the drugs. Data obtained

2012 Indian journal of pediatrics Controlled trial quality: uncertain

18. A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. Full Text available with Trip Pro

A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. Some anticonvulsants ameliorate signs and symptoms of alcohol withdrawal, but have an unacceptable side effect burden. Among the advantages of using anticonvulsant agents in this capacity is their purported lack of interaction with alcohol that could increase psychomotor deficits, increase cognitive impairment, or increase intoxication. The aim of this study was to evaluate alcohol use and symptom (...) reduction of gabapentin when compared with lorazepam in the treatment of alcohol withdrawal in a double-blinded randomized clinical trial.One hundred individuals seeking outpatient treatment of alcohol withdrawal with Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar) ratings > or =10 were randomized to double-blind treatment with 2 doses of gabapentin (900 mg tapering to 600 mg or 1200 tapering to 800 mg) or lorazepam (6 mg tapering to 4 mg) for 4 days. Severity of alcohol

2009 Alcoholism, clinical and experimental research Controlled trial quality: uncertain

19. Comparative efficacy of baclofen and lorazepam in the treatment of alcohol withdrawal syndrome. (Abstract)

Comparative efficacy of baclofen and lorazepam in the treatment of alcohol withdrawal syndrome. Benzodiazepines (BDZs) have been the treatment of choice for alcohol withdrawal syndrome (AWS); however, they are associated with several side effects and also have abuse potential. In some studies, the use of baclofen has been effective in reducing symptoms of alcohol withdrawal symptoms.The objective of this study was to compare the efficacy of baclofen and benzodiazepine (lorazepam) in reducing (...) symptoms of AWS.It was a single-center, randomized, open-label study. Patients with alcohol dependence syndrome were enrolled in the study and randomized into two groups using computer-generated random table number. Baclofen (experimental group, 10 mg three times a day) and BZDs (control group, lorazepam, 8-12 mg/day in divided doses) were orally administered for reducing symptoms of alcohol withdrawal. Both groups received Vitamin B1 (100 mg/day through intramuscular route) and psychotherapeutic

2019 Indian journal of psychiatry Controlled trial quality: uncertain

20. A double-blind controlled trial of lorazepam and diazepam in the treatment of anxiety. (Abstract)

A double-blind controlled trial of lorazepam and diazepam in the treatment of anxiety. 4589712 1974 03 21 2013 11 21 0300-7995 1 5 1973 Current medical research and opinion Curr Med Res Opin A double-blind controlled trial of lorazepam and diazepam in the treatment of anxiety. 265-8 Eaves D D Jain V K VK Swinson R P RP eng Clinical Trial Comparative Study Controlled Clinical Trial Journal Article Randomized Controlled Trial England Curr Med Res Opin 0351014 0300-7995 0 Benzodiazepinones 0

1974 Current medical research and opinion Controlled trial quality: uncertain